Xcout IntelOdyssey Therapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Odyssey Therapeutics, Inc. among biotech companies — ranked by similarity to what Odyssey Therapeutics, Inc. actually does, not by market-cap band.
Subscribe to see Odyssey Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
Odyssey Therapeutics, Inc. at a glance
Odyssey Therapeutics, Inc. is a biotech company headquartered in Boston, United States, founded in 2000. It is publicly listed (ODTX) with a market capitalisation of $870.8M. Xcout tracks 38 named people at Odyssey Therapeutics, Inc., including Gary D. Glick (President & CEO).
Odyssey Therapeutics, Inc. leadership
- Gary D. GlickPresident & CEO
- Jason HaasChief Financial Officer
- Joseph McDonaldChief Data Officer
- Natalie DalesChief of Research Operations & Portfolio Strategy
- Gary D. GlickFounder, President, CEO & Director
- Gary Glickfounder, president and CEO
32 more named people on record for Odyssey Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Odyssey Therapeutics, Inc. funding rounds before its IPO
The 3 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series D | $213M | 6 named | |
| Series D | $117.2M | 7 named | |
| — | $168M | 6 named |
Financing after the IPO — public offerings and SEC Form D private placements — is not listed as a funding round.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Odyssey Therapeutics, Inc. news
3 corporate events on record, with sources — see the full timeline →
Top 12 Odyssey Therapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to Odyssey Therapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.
Similar biotech company
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Biotechnology
Apogee Therapeutics is a biotechnology company focused on the development of therapies for inflammatory and immunology diseases. The company is headquartered in Waltham, Massachusetts.
Biotechnology
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. Headquartered in California, the company advances a robust clinical pipeline and operates as a publicly traded enterprise.
Similar biotech company
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Similar biotech company
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
Biotechnology
Expedition Therapeutics is a clinical-stage biotechnology company headquartered in San Francisco, California, developing novel oral small molecule therapies for serious inflammatory and respiratory diseases.
Biotechnology
Sundance Biosciences is a biotechnology company founded in 2025 and headquartered in South San Francisco, California. The firm focuses on developing oral therapies that selectively target TYK2 to modulate immune responses for treating complex diseases.
Biotechnology
Rezera Inc., formerly known as NodThera, is advancing oral anti-inflammatory NLRP3 inhibitors, including the Ruvonoflast Phase 3 development program, with headquarters in Boston.
Biotechnology
Ouro Medicines is a biotechnology company headquartered in South San Francisco, California, developing immune reset therapeutics for chronic immune-mediated diseases.
Biotechnology
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
Biotechnology
Mysthera Therapeutics AG is a biotechnology company headquartered in Basel, Switzerland, focused on developing first-in-class, oral therapeutics to treat inflammation-driven and related diseases.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Odyssey Therapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Odyssey Therapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →